scholarly journals Long-term outcome of transjugular intrahepatic portosystemic shunt for portal hypertension in autosomal recessive polycystic kidney disease

2018 ◽  
Vol 50 (7) ◽  
pp. 707-712 ◽  
Author(s):  
Sarah Verbeeck ◽  
Djalila Mekhali ◽  
David Cassiman ◽  
Geert Maleux ◽  
Peter Witters
Keyword(s):  
Portal Hypertension ◽  
Kidney Disease ◽  
Transjugular Intrahepatic Portosystemic Shunt ◽  
Autosomal Recessive ◽  
Portosystemic Shunt ◽  
Polycystic Kidney ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Intrahepatic Portosystemic Shunt

Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors

1997 ◽  
Vol 11 (3) ◽  
pp. 302-306 ◽  
Author(s):  
Sushmita Roy ◽  
Michael J. Dillon ◽  
Richard S. Trompeter ◽  
T. Martin Barratt
Keyword(s):  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Recessive ◽  
Polycystic Kidney ◽  
Term Outcome ◽  
Long Term Outcome

Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome

2008 ◽  
Vol 28 (2) ◽  
pp. 249-256 ◽  
Author(s):  
Sarwa Darwish Murad ◽  
Trinh K. Luong ◽  
Peter M. T. Pattynama ◽  
Bettina E. Hansen ◽  
Henk R. Van Buuren ◽  
...  
Keyword(s):  
Transjugular Intrahepatic Portosystemic Shunt ◽  
Portosystemic Shunt ◽  
Budd Chiari Syndrome ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Chiari Syndrome ◽  
Intrahepatic Portosystemic Shunt

scholarly journals Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and post-transjugular intrahepatic portosystemic shunt complications in 2020

2020 ◽  
pp. 205064062095263 ◽  
Author(s):  
Adelina Horhat ◽  
Christophe Bureau ◽  
Dominique Thabut ◽  
Marika Rudler
Keyword(s):  
Portal Hypertension ◽  
Transjugular Intrahepatic Portosystemic Shunt ◽  
Variceal Bleeding ◽  
Portosystemic Shunt ◽  
Venous System ◽  
Refractory Ascites ◽  
Special Focus ◽  
Long Term Outcome ◽  
Shunt Complications ◽  
Intrahepatic Portosystemic Shunt

Transjugular intrahepatic portosystemic shunt is a percutaneous radiologic-guided procedure that aims to reduce portal hypertension by creating a shunt between the portal venous system and the hepatic venous system. The most common cause of portal hypertension is liver cirrhosis in Western countries. Two main indications of transjugular intrahepatic portosystemic shunt are validated by randomised controlled studies in patients with cirrhosis and variceal bleeding (salvage transjugular intrahepatic portosystemic shunt, early-transjugular intrahepatic portosystemic shunt or rebleeding despite an optimal secondary prophylaxis) or refractory ascites. Careful selection of the patients is crucial in order to prevent post-transjugular intrahepatic portosystemic shunt complications, including liver failure, post-transjugular intrahepatic portosystemic shunt encephalopathy occurrence and cardiac decompensation, for a better long-term outcome. In this review, we will discuss transjugular intrahepatic portosystemic shunt indications in 2020 in patients with cirrhosis and portal hypertension, with a special focus on variceal bleeding and refractory ascites. Then, we will describe transjugular intrahepatic portosystemic shunt-related complications, the contraindications and the current knowledge on patient’s selection.

Long-Term Outcome of Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease

1990 ◽  
Vol 15 (6) ◽  
pp. 535-543 ◽  
Author(s):  
Peter M. Fitzpatrick ◽  
Vicente E. Torres ◽  
J. William Charboneau ◽  
Kenneth P. Offord ◽  
Keith E. Holley ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Autosomal Dominant Polycystic Kidney
Sign in / Sign up

Export Citation Format

Share Document